InvestorsHub Logo
Followers 42
Posts 4850
Boards Moderated 0
Alias Born 08/06/2012

Re: Peacefulwendy post# 48581

Monday, 05/16/2016 10:20:05 PM

Monday, May 16, 2016 10:20:05 PM

Post# of 144815
There lies a problem I've mentioned before. Pancreatic cancer spreads very quickly. Find patients that meet the criteria will be slim to none. Pmcb cannot compete head to head so they opted to take the leftovers so to speak. Unfortunately those patients will be in to bad of shape to fit the criteria.


Quote:
"Only patients who have locally advanced, non-metastatic, inoperable cancers and whose tumors no longer respond after 4-6 months of treatment with either the nab-paclitaxel (Abraxane®) + gemcitabine or FOLFIRINOX regimens will be eligible for the study. "

Disclosure: I am a involved in and support the SEC whistleblower program, I may be rewarded cash for information that leads to the successful enforcement by the SEC of a federal court or administrative action in $1m+.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News